Palo Alto Investors LP Aprea Therapeutics, Inc. Transaction History

Palo Alto Investors LP

$790 Million
Q2 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 17, 2021	SELL	$4.73 - $8.15 $609,082 - $1.05 Million	-128,770 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$4.92 - $30.67 $44,132 - $275,109	8,970 Added 7.49%	128,770 $634,000
Q3 2020 Nov 16, 2020	BUY	$21.66 - $38.86 $1.57 Million - $2.82 Million	72,566 Added 153.63%	119,800 $2.88 Million
Q2 2020 Aug 14, 2020	BUY	$25.47 - $39.69 $1.2 Million - $1.87 Million	47,234 New	47,234 $1.83 Million

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$3,775
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.